S'pore firm to acquire 73% in Dabur Pharma

Singapore-based Fresenius Kabi Pte Ltd is set to acquire approximately 73.27 per cent of the total issued and paid-up equity share capital of Dabur Pharma at Rs 76.50 per share, the company informed the BSE today.

Dabur Pharma is an associate compnay of Dabur India Ltd and has a business focus in bulk drugs and the formulation business.

The acquisition is subjet to the fulfillment of Sebi regulatory guidelines and the compliance by Fresenius with public offer requirements. Dabur Pharma stock traded at Rs 69.15 on April 17, the stock price may rise after the markets open on Monday say experts.